Design and Modification of Anticancer PeptidesCuihua Hu1,3, Xiaolong Chen1,3, Wencai Zhao1,3, Yuxin Chen1-3, Yibing Huang1-3*
- Corresponding Author:
- Yibing Huang
Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education
College of Life Sciences, Jilin University
2699 Qianjin Street, Changchun, China
E-mail: [email protected]
Received date: November 02, 2016; Accepted date: November 22, 2016; Published date: November 29, 2016
Citation: Hu C, Chen X, Zhao W, Chen Y, Huang Y (2016) Design and Modification of Anticancer Peptides. Drug Des 5:138. doi:10.4172/2169-0138.1000138
Copyright: © 2016 Hu C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cancer is a great concern in the public health and development of novel therapeutic agent or strategy become urgently. Anticancer peptides (ACPs) have become promising anticancer drug candidate molecules due to their several extraordinary properties, such as small size, high activity, low immunogenicity, good biocompatibility, diversity of sequence and more modification sites for the functional molecules. However, the low stability and short half-life of peptides are the major barriers for the application. In this review, we focus on the methods of peptide design and modification to improve the stability, half-life time and specificity of ACPs, which including amino acid substitution, cyclization, hybridization, fragmentization, modification of C- and N-terminal of peptide by polymer or targeting molecules, etc.